Abstract
ObjectiveRenal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Early detection is the effective way to improve the prognosis of patients with renal cell carcinoma. In the development and progression of cancer accompanied by metabolic changes, so metabolomics has special advantages in diagnosis of RCC. The aim of this study is to find discriminating metabolites from RCC through a non-target metabolomics method.MethodsWe extracted the serum samples of RCC patients and controls for HPLC-MS detection, and used quantitative analysis of multivariate statistical methods were employed to analyze the data.ResultsIn this study, we found that the metabolite in RCC significantly different from the controls, metabolic pathways including arachidonic acid and sphingolipid metabolism were found to be disturbed in RCC patients compared with controls.ConclusionsMetabolite concentration in cells of the system change is most likely to switch to immune response and energy balance. This study indicates that metabolomics may be a valuable tool for the discovery of novel cancer biomarkers in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
